|
|
Article: rhATIII PK study completed.(recombinant human antithrombin III )(pharmacokinetic)(Brief Article)
- Article from:
- Proteomics Weekly
- Article date:
- August 26, 2002
CopyrightCOPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2002 AUG 26 - (NewsRx.com & NewsRx.net) -- GTC Biotherapeutics, Inc., (GTC) has completed data gathering and analysis in the pharmacokinetic study of recombinant human antithrombin III (rhATIII) in patients with a hereditary deficiency of the antithrombin blood protein.
In accordance with good scientific practice, the results have been submitted for peer review and presentation at the British Society for Haemostatis and Thrombosis annual scientific meeting September 4-6, 2002. There were 15 healthy adult HD patients in the PK study, each monitored over a 6-day period. This study primarily assessed whether there were any immunologic responses and how long rhATIII ...